ORANGE COUNTY, Calif., March 12 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC - News), a leading developer, and manufacturer of products that simplify and automate complex biomedical testing, announced today that it has launched the Gallios Flow Cytometer, the first of several instrument, software and reagent introductions in the year for both clinical and research applications in flow cytometry.
The new Gallios Flow Cytometer, targeted to the research market, delivers analytical excellence combined with high speed data collection. Features - including advanced optics, patented electronics design, and novel software tools - improve lab workflow and quality control, delivering increased sensitivity and resolution in less time and at higher speeds. Researchers can readily see small and subtle changes in cell populations, and the system accelerates data generation.
“Every aspect of the Gallios design increases application performance. When combined with our broad and high quality reagent portfolio, we provide a new and powerful solution for cellular analysis, increasing productivity and improving the reliability and reproducibility of results,” said Cynthia Collins, group vice president of Cellular Analysis at Beckman Coulter.
The analyzer’s efficient, compact design allows laboratories to maximize valuable space. The system comes in three scaleable configurations that allow for future addition of more lasers and fluorescence detectors as the need for complex multi-color flow cytometry expands.
Collins added, “We are adding a number of exciting products to our flow cytometry portfolio this year. They are a testament to our commitment to enhancing the efficiency of flow cytometry laboratories around the globe.”
About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company’s 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.
Contacts: Mary Luthy, Beckman Coulter Corporate Communications (714) 773-7964
